Cardiff Oncology (CRDF) Gross Margin (2014 - 2019)
Cardiff Oncology (CRDF) posted Gross Margin of 100.0% for Q4 2019, little changed sequentially from 100.0% in Q3 2019, and little changed YoY from 100.0% in Q4 2018.
Cardiff Oncology (CRDF) Gross Margin (2014 - 2019) Analysis & Trends
Cardiff Oncology has reported Gross Margin for 6 years, with the latest figure at 100.0% in Q4 2019.
- Quarterly Gross Margin changed 0.0% year-over-year to 100.0% in Q4 2019, while the trailing twelve-month figure through Dec 2019 was 100.0% (up 18257.0% YoY) and the FY2019 annual result came in at 100.0%, up 15792.0% from the prior year.
- Gross Margin was little changed at 100.0% in Q4 2019 per CRDF's latest filing, from 100.0% in the prior quarter.
- Over five years, Gross Margin peaked at 100.0% in Q4 2018 and troughed at 836.45% in Q1 2017.
- A 5-year average of 204.29% and a median of 129.75% in 2015 frame the typical range for Gross Margin.
- The sharpest annual moves came in 2017 and 2018: Gross Margin slumped 67872 bps in 2017, then jumped 77486 bps in 2018.
- Over 5 years, Gross Margin stood at 152.15% in 2015, then slumped by 402 bps to 763.56% in 2016, then jumped by 86 bps to 107.35% in 2017, then surged by 193 bps to 100.0% in 2018, then changed by 0 bps to 100.0% in 2019.
- According to Business Quant data, Gross Margin over the past three periods registered 100.0%, 100.0%, and 100.0% for Q4 2019, Q3 2019, and Q2 2019 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 85.33% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 91.59% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 90.43% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 35.86% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 89.76% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 76.90% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 63.27% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 84.20% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Cardiff Oncology | 60.21 Mn | 60.21 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2019 | 100.00% |
| Sep 30, 2019 | 100.00% |
| Jun 30, 2019 | 100.00% |
| Mar 31, 2019 | 100.00% |
| Dec 31, 2018 | 100.00% |
| Sep 30, 2018 | 69.81% |
| Jun 30, 2018 | -82.84% |
| Mar 31, 2018 | -646.80% |
| Dec 31, 2017 | -107.35% |
| Sep 30, 2017 | -705.05% |
| Jun 30, 2017 | -231.54% |
| Mar 31, 2017 | -836.45% |
| Dec 31, 2016 | -763.56% |
| Sep 30, 2016 | -377.03% |
| Jun 30, 2016 | -293.71% |
| Mar 31, 2016 | -157.73% |
| Dec 31, 2015 | -152.15% |
| Sep 30, 2015 | -199.20% |
| Jun 30, 2015 | -63.33% |
| Mar 31, 2015 | -38.92% |